These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 23692584)

  • 21. Economic costs associated with an MS relapse.
    O'Connell K; Kelly SB; Fogarty E; Duggan M; Buckley L; Hutchinson M; McGuigan C; Tubridy N
    Mult Scler Relat Disord; 2014 Nov; 3(6):678-83. PubMed ID: 25891546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.
    Orme M; Kerrigan J; Tyas D; Russell N; Nixon R
    Value Health; 2007; 10(1):54-60. PubMed ID: 17261116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Uitdehaag B; Kobelt G; Berg J; Capsa D; Dalén J;
    Mult Scler; 2017 Aug; 23(2_suppl):117-129. PubMed ID: 28643595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain.
    Casado V; Romero L; Gubieras L; Alonso L; Moral E; Martinez-Yelamos S; Martinez-Yelamos A; Carmona O; Arbizu T
    Mult Scler; 2007 Jul; 13(6):800-4. PubMed ID: 17613609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Lonergan R; Kinsella K; Duggan M; Jordan S; Hutchinson M; Tubridy N
    Mult Scler; 2009 Dec; 15(12):1528-31. PubMed ID: 19995848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
    Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
    J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
    [No Abstract]   [Full Text] [Related]  

  • 27. Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors.
    Krause I; Kern S; Horntrich A; Ziemssen T
    Mult Scler; 2013 Nov; 19(13):1792-9. PubMed ID: 23635910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
    Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
    J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health status and costs of ambulatory patients with multiple sclerosis in Hungary.
    Péntek M; Gulácsi L; Rózsa C; Simó M; Iljicsov A; Komoly S; Brodszky V
    Ideggyogy Sz; 2012 Sep; 65(9-10):316-24. PubMed ID: 23126217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP).
    Wynia K; van Wijlen AT; Middel B; Reijneveld SA; Meilof JF
    Mult Scler; 2012 May; 18(5):654-61. PubMed ID: 21965423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic burden of multiple sclerosis in a population with low physical disability.
    García-Domínguez JM; Maurino J; Martínez-Ginés ML; Carmona O; Caminero AB; Medrano N; Ruíz-Beato E;
    BMC Public Health; 2019 May; 19(1):609. PubMed ID: 31109317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.
    Jones E; Pike J; Marshall T; Ye X
    BMC Health Serv Res; 2016 Jul; 16():294. PubMed ID: 27443278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
    Rotstein Z; Hazan R; Barak Y; Achiron A
    Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient reported outcomes in benign multiple sclerosis.
    Hviid LE; Healy BC; Rintell DJ; Chitnis T; Weiner HL; Glanz BI
    Mult Scler; 2011 Jul; 17(7):876-84. PubMed ID: 21372114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost of multiple sclerosis in Australia.
    Taylor B; McDonald E; Fantino B; Sedal L; MacDonnell R; Pittas F; Groom T; Beresniak A
    J Clin Neurosci; 2007 Jun; 14(6):532-9. PubMed ID: 17430777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
    Sayao AL; Bueno AM; Devonshire V; Tremlett H;
    Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis.
    Kobelt G; Berg J; Lindgren P; Jönsson B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S5-13. PubMed ID: 17310344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Societal costs of multiple sclerosis in Ireland.
    Carney P; O'Boyle D; Larkin A; McGuigan C; O'Rourke K
    J Med Econ; 2018 May; 21(5):425-437. PubMed ID: 29320900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The societal burden of pain in Germany: health-related quality-of-life, health status and direct medical costs.
    Langley PC
    J Med Econ; 2012; 15(6):1201-15. PubMed ID: 22835007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.